Metastasis-associated protein 1 is a novel marker predicting survival and lymph nodes metastasis in cervical cancer.
Metastasis-associated gene 1 (MTA1), which is involved in tumor progression, metastasis, and angiogenesis, has been examined in several malignant tumors. However, the expression and the effect of MTA1 on human cervical cancer remain unknown. In this study, we investigated the level of MTA1 expression in cervical carcinoma and its clinical significance. By immunohistochemical staining, the correlation of MTA1 overexpression with clinical features and patient outcome was analyzed in 132 formalin-fixed, paraffin-embedded cervical cancer tissues. MTA1 protein overexpression was detected in 73 (55.3%) of 132 patients. High levels of MTA1 protein were clearly correlated with histologic grade (P = .006), lymph node metastasis (P = .001), and recurrence (P = .016). Multivariate Cox analysis showed that MTA1 was an independent factor for overall survival (hazard ratio, 3.486; 95% confidence interval [CI], 1.274-9.537; P = .015) and disease-free survival (hazard ratio, 3.373; 95% CI, 1.212-9.387; P = .020). Multivariate logistic regression analysis indicated that elevated MTA1 was strongly associated with lymph node metastasis (odds ratio, 3.879; 95% CI, 1.391-10.816; P = .010). Sensitivity and specificity were calculated as 81.25% and 53.0%, respectively. These findings suggest that MTA1 nuclear overexpression is associated with tumor progression and metastasis and thus support its clinical significance in future gene-targeted therapies, particularly the management of patients with cervical cancer.